BTIG raised the firm’s price target on Theravance Biopharma (TBPH) to $25 from $24 and keeps a Buy rating on the shares. Yupelri has been approved in China, triggering the $7.5M milestone payment owed to the company, the analyst tells investors in a research note. Looking ahead, Theravance is eligible to receive up to $37.5M in sales-based milestones and 14%-20% tiered royalties on Yupelri net sales in China in addition to the milestone payment, the firm added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma Gains Milestone Payment from Viatris
- Theravance Biopharma announces Viatris approval for Yupelri in China
- Theravance Biopharma initiated with a Buy at JonesResearch
- Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment
- Theravance Biopharma Settles Patent Litigation with Eugia